Last reviewed · How we verify
TLPLDC
At a glance
| Generic name | TLPLDC |
|---|---|
| Sponsor | Elios Therapeutics, LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Autologous TLPO Vaccine Basket (PHASE2)
- Phase IIB TL + YCWP + DC in Melanoma (PHASE2)
- Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TLPLDC CI brief — competitive landscape report
- TLPLDC updates RSS · CI watch RSS
- Elios Therapeutics, LLC portfolio CI